7082 results for "canc*"

in 9.06 milliseconds.

• Targeted sequencing of HGS-EOC samples

  A 19-sample data set containing data from FFPE high grade serous ovarian cancer biopsies. The library was made with a custom hybridization kit (EZ-Cap, Roche) spanning 7 genes.

  Dataset EGAD00001006064

• Tumour sample for patient SA605

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA605

  Dataset EGAD00001009261

• NKI-AvL CRC-OVC DNA-seq

  The dataset “NKI-AvL CRC-OVC DNA-seq" includes 4 normal and 4 tumor BAM files from paired-end whole exome sequencing on Illumina HiSeq2500 and Illumina NovaSeq6000 for 2 colorectal cancer and 2 ovarian cancer patients.

  Dataset EGAD00001004340

• BC WGS Dataset

  We propose to definitively characterise the somatic genetics of breast cancer through generation of comprehensive catalogues of somatic mutations in breast cancer cases by high coverage genome sequencing coupled with integrated transcriptomic and methylation analyses.

  Dataset EGAD00001001338

• Shallow whole genome sequencing on stage 1 epithelial ovarian cancer

  BAM files (aligned against the hg38 genome) from a shallow whole-genome sequencing experiment (median depth 0.5X) on 218 samples from Stage 1 epithelial ovarian cancer biopises. Samples labeled "bis" or "tris" with the same ID are relapses; "left" or "right" samples indicate, in the case of bilateral tumor, from which ovary the sample was taken.

  Dataset EGAD00001006881

• Ovarian Cancer Organoid Biobank

  WGS of ovarian cancer organoids, tumor samples and blood references. Ovarian cancer (OC) is a heterogeneous disease usually diagnosed at a late stage. Experimental in vitro models that faithfully capture the hallmarks and tumor heterogeneity of OC are limited and hard to establish. We present a novel protocol that enables efficient derivation and long-term expansion of OC organoids. Utilizing this protocol, we have established 56 organoid lines from 32 patients, representing the spectrum of ovarian neoplasms, including non-malignant borderline tumors, as well as mucinous, clear-cell, endometrioid, low- and high-grade serous carcinomas. OC organoids recapitulate histological and genomic features of the pertinent lesion from which they were derived, illustrating intra- and inter-patient heterogeneity, and can be genetically modified. We show that OC organoids can be used for drug screening assays and capture different tumor subtype responses to the gold standard platinum-based chemotherapy, including acquisition of chemoresistance in recurrent disease. Finally, OC organoids can be xenografted, enabling in vivo drug sensitivity assays. Taken together, this demonstrates their potential application for research and personalized medicine.

  Dataset EGAD00001004387

• Normal sample for patient SA669

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA669

  Dataset EGAD00001009255

• Normal sample for patient SA671

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA671

  Dataset EGAD00001009256

• Tumour sample for patient SA994

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA994

  Dataset EGAD00001009259

• Tumour sample for patient SA609

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA609

  Dataset EGAD00001009262